323 related articles for article (PubMed ID: 25903392)
1. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
3. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Hughes DA; Gonzalez DE; Lukina EA; Mehta A; Kabra M; Elstein D; Kisinovsky I; Giraldo P; Bavdekar A; Hangartner TN; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
[TBL] [Abstract][Full Text] [Related]
4. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
5. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
Zimran A; Altarescu G; Philips M; Attias D; Jmoudiak M; Deeb M; Wang N; Bhirangi K; Cohn GM; Elstein D
Blood; 2010 Jun; 115(23):4651-6. PubMed ID: 20299511
[TBL] [Abstract][Full Text] [Related]
11. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
[TBL] [Abstract][Full Text] [Related]
12. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
13. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468
[TBL] [Abstract][Full Text] [Related]
14. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
16. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
[TBL] [Abstract][Full Text] [Related]
18. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]